Terumo Corp – Lobbying Governance & Transparency

Sign up to access all our data and the evidence and analysis underlying our overall scores. Once you've created an account, we'll get in touch with further details:

Lobbying Governance

Overall Assessment	Analysis	Score
Moderate	Terumo Corp outlines a structured process for aligning its policy engagement with its climate change strategy under the oversight of its Terumo Group EHS Committee and Executive Management Meeting. For instance, it explains that “important issues are placed on the agenda of the Terumo Group EHS Committee and the Executive Management Meeting to ensure consistency with the Company’s climate change strategy” and that it “report[s] back to the Terumo Group EHS Committee” after seminars on climate issues. The company leverages indirect lobbying channels by stating “We are members of FPMAJ (Federation of Pharmaceutical Manufacturers’ Associations of Japan) and The Intravenous Solution Society to ensure that our views are reflected and that public policy is consistent with our strategy” and through participation in the Japan Climate Initiative, where it “announced our support for a message calling for a 40-50% renewable electricity target for FY2030.” It further notes that if a conflict arises, “the EHS Committee will discuss the conflict ... and recommend a direction to each organization based on our thinking,” indicating a formal mechanism to resolve misalignment. However, the company does not disclose any specific individual responsible for lobbying oversight, nor does it describe a dedicated process for governing direct lobbying engagement beyond association memberships, leaving key governance elements around direct lobbying and defined officer roles unclear. View Sources	C

Overall Assessment

Analysis

Score

Moderate

Terumo Corp outlines a structured process for aligning its policy engagement with its climate change strategy under the oversight of its Terumo Group EHS Committee and Executive Management Meeting. For instance, it explains that “important issues are placed on the agenda of the Terumo Group EHS Committee and the Executive Management Meeting to ensure consistency with the Company’s climate change strategy” and that it “report[s] back to the Terumo Group EHS Committee” after seminars on climate issues. The company leverages indirect lobbying channels by stating “We are members of FPMAJ (Federation of Pharmaceutical Manufacturers’ Associations of Japan) and The Intravenous Solution Society to ensure that our views are reflected and that public policy is consistent with our strategy” and through participation in the Japan Climate Initiative, where it “announced our support for a message calling for a 40-50% renewable electricity target for FY2030.” It further notes that if a conflict arises, “the EHS Committee will discuss the conflict ... and recommend a direction to each organization based on our thinking,” indicating a formal mechanism to resolve misalignment. However, the company does not disclose any specific individual responsible for lobbying oversight, nor does it describe a dedicated process for governing direct lobbying engagement beyond association memberships, leaving key governance elements around direct lobbying and defined officer roles unclear.

View Sources

Lobbying Transparency

Overall Assessment	Analysis	Score
None	No evidence found	E